The Latest Breaking News from FDA

Here's a roundup of top developments in the biotech space over the last 24 hours:

FDA’s action follows its advisory panel’s unanimous recommendation for the shots from Moderna and Pfizer

COVID vaccines for children ages 5 and under from Pfizer Inc. and Moderna Inc. received authorization from U.S. regulators, meaning almost all of the American population can soon get protected against COVID-19 disease.

The FDA authorized Pfizer's and Moderna's Covid shots for children as young as 6 months old Friday, but the vaccine stocks diverged.

The United States Food and Drug Administration (FDA) has granted Orphan Drug Designation to Kazia Therapeutics’ (NASDAQ: KZIA) Paxalisib for the treatment of atypical rhabdoid / teratoid tumors (AT/RT), a rare and highly-aggressive childhood brain cancer.

The shots could start being administered as early as next week.

U.S. regulators have authorized the first COVID-19 shots for infants and preschoolers

Whether or not you’ve heard of the chemical bisphenol A, better known as BPA, studies show that it’s almost certainly in your body. BPA is used in the manufacturing of products like plastic water bottles, baby bottles, toys and food packaging, including in the lining of cans.

Rhythm Pharmaceuticals Inc (NASDAQ:RYTM) entered into a Revenue Interest Financing Agreement with HealthCare Royalty Partners for a total investment of $100 million.  Rhythm intends to use the proceeds to support global commercialization efforts for its newly approved Imcivree (setmelanotide) and ongoing clinical development. With this new approval, Imcivree is indicated for chronic weight management…

One and a half years after the adult COVID-19 vaccine, a kids' shot is here. This is why it took so much longer

Gov. Ron DeSantis on Thursday defended the state’s decision not to preorder COVID-19 pediatric vaccines for children under 5, saying that parents who want the shots can access them without the state’s help.